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Hyperhidrosis palmaris (HP) is a rather common disease in Taiwan. Taiwan is a leading nation 
in terms of the surgical treatment of this disease using thoracic endoscopic sympathectomy.
However, the currently available epidemiological information regarding HP is insufficient. 
To date, the incidence of HP and the percentage of patients treated surgically have not been
reported. We investigated the incidence of HP treated in 2004 by sampling Taiwan’s National
Health Insurance database. Patients who were diagnosed with HP during 2004 were identified
by International Classification of Diseases, 9th Clinical Modification code 780.8 from a database of
about 22 million beneficiaries, and were followed to 2006. Those who had been diagnosed as HP
in 2002 or 2003 were excluded. Patients who underwent surgery were identified by the treatment
codes 83026C (dorsal sympathectomy) and 83085B (transendoscopic dorsal sympathectomy,
TES). Factors included in the analysis included age, sex, time of operation and hospitalization for
surgery. In total, 15,839 patients with HP were identified. The incidence was 7.2 per 10,000 bene-
ficiaries. The study sample included 7,603 males with an incidence of 6.9 per 10,000 beneficiaries,
and 8,236 females with an incidence of 7.4 per 10,000 beneficiaries. The incidence was highest
among patients aged 20–29 years old. The incidence decreased with increasing age (Mantel-
Haenszel χ2 test for trend, p < 0.001), and 3,755 cases (23.7%) received an operation, of which 1,733
were male (22.8% of all male patients) and 2,022 were female (24.6% of all female patients)
(p = 0.009). Of these, 99.3% underwent transendoscopic dorsal sympathectomy, and 94.7% under-
went surgery within 1 month of the initial diagnosis. Males underwent surgery sooner than females
(p = 0.004). Adjusted multivariate logistic regression analysis showed that patients aged 20–29
were more likely to undergo surgery than the other age groups (odds ratio: 2.28; 95% confidence
interval: 2.07–2.52). Regional hospitals had the highest chance to perform the operation (odds
ratio: 4.87; 95% confidence interval: 4.41–5.37). Here, we have reported the incidence of HP in
Taiwan in 2004 and concluded that the incidence was higher in females than in males. About one-
quarter of patients underwent surgery, mostly within 1 month after attending an outpatient
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clinic; most surgical interventions involved endoscopic sympathectomy. This report fulfills 
the epidemiological information gap of HP and provides important data for future health care
delivery.
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Primary hyperhidrosis palmaris (HP) is an excessive
perspiration of hands that interferes with social in-
teractions, emotional well-being, and professional
activities [1–3]. However, the cause of hyperhidrosis
is still unknown. Patients with this excessive non-
thermoregulatory sweat response [4] often show sym-
pathetic overactivity and compensatory increased
parasympathetic activity, which can be demonstrated
by power spectrum analysis [5].
Hyperhidrosis is mainly found at the palms, soles,
and axillae [1,4,6–9]. Palmar hyperhidrosis is the most
frequent presentation type of this sudomotor regula-
tion disorder [9]. However, the prevalence seems to be
higher in Western countries (up to 51%) and people
show greater concern about axillary hyperhidrosis than
Asian people [8,10]. Hyperhidrosis has an ethnic pre-
ponderance [11,12] and frequently shows a familial
predisposition [1,2,8,9,13]. There is some evidence of
vertical transmission [2], but there is still no evidence
for an association with genetic polymorphisms [14].
Diagnosis of this disorder is mainly based on the
patient’s subjective complaints. Minor’s iodine-starch
test [4], gravimetric quantification, power spectrum
analysis of heart rate variability [5], and skin responses
[15] add little to the diagnosis of hyperhidrosis [10]
or surveying its incidence in the general population.
The treatment options for hyperhidrosis include anti-
perspirants, anticholinergic drugs, iontophoresis,
surgery, and botulinum toxin injection [16]. Surgical
treatment by thoracic endoscopic sympathectomy
(TES) is reported to be more effective than and superior
to medication [1,6,17,18]. Taiwan is a leading nation
in terms of using this surgical technique [1,6,19–21].
To our knowledge, there are only three epidemio-
logical studies of hyperhidrosis [2,3,10,13], and all
report prevalence instead of incidence. A pilot study
reported a prevalence of 0.6–1.0% among young
Israelis [12]. A survey among adolescent Chinese
reported a prevalence of 4.36% [9,13]. Strutton et al
reported that 2.8% of the general population in the
United States had hyperhidrosis across all ages, loca-
tions, and severities [10]. However, none of the above
studies measured the actual incidence of treated hyper-
hidrosis and the frequency of patients who underwent
surgical treatment.
Taiwan’s National Health Insurance (NHI) is a
universal health insurance program that covers more
than 98% of the total population in Taiwan [22]. We
investigated the age- and sex-specific incidence of the
disease, and the frequency of surgical treatment in
2004, by sampling Taiwan’s NHI database.
METHODS
Data were retrieved from Taiwan’s NHI database
[22]. Briefly, the NHI plan was implemented in 1995
and has since accumulated 22.28 million administra-
tive and claims records, and covers approximately 98%
of the total population of Taiwan [23]. These database
form the largest such collection in the world. The
NHI Bureau (NHIB) has established a uniform sys-
tem to control the quality of medical services. Patient
treatment is controlled by a Professional Peer Review
Committee and a Disputes Settlement Board to ensure
a high standard of treatment by the contracted hospi-
tals, doctors, and other relevant medical care institu-
tions. The National Health Research Institute (NHRI)
cooperated with the NHIB to establish a NHI research
database. The NHRI safeguards the privacy and con-
fidentiality of the subjects, and routinely transfers the
health insurance data from the NHIB to their own
database to enable health researchers to analyze and
improve the health of citizens in Taiwan. This system
provides a highly reliable database containing patient
treatment statistics to researchers.
The incidence of treated HP was evaluated on the
basis of the above academic cohort database. A de-
identified dataset (both patients and physicians are
de-identified) was extracted for 2002–2006. The NHI
diagnostic coding used in Taiwan is in accordance
with the International Classification of Diseases, 
9th Clinical Modification (ICD-9-CM). The ICD-9-CM
code 780.8 was used to define hyperhidrosis and in-
cludes diaphoresis and excessive sweating. Patients
who were diagnosed with HP in 2004 were identified
by the ICD-9-CM code 780.8 in the dataset, which
covers hospital administrative and outpatient data.
Data from all age groups were included. Patients
diagnosed with HP in 2002 or 2003 were excluded
from this study.
Patients identified with code 780.8 in 2004 were
followed-up until the end of 2006 for any operation
to treat hyperhidrosis. Surgery to treat hyperhidrosis
was identified by the treatment codes 83026C (dorsal
sympathectomy, DS) or 83085B (thoracic endoscopic
sympathectomy, TES). The incidence of treatment for
HP was calculated and possible associated factors,
such as age, sex, time of operation, and the hospital
where the surgery took place, were also included in
the analysis. The percentage of diagnosed patients
who underwent surgery to treat HP and the factors
affecting their choice of surgical treatment were in-
vestigated. The study was approved by the hospital
institutional review board on August 26, 2008, with a
waiver for informed consent.
Statistical analysis
The data was expressed as the number of cases and
as percentages. Pearson’s χ2 test was used to evaluate
the significance of differences between groups. The
Mantel-Haenszel χ2 test was used to examine trends.
Logistic regression was used for multivariate analy-
ses. A p value of less than 0.05 was regarded as sig-
nificant. All analyses were performed using SPSS
version 13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 15,839 patients were newly diagnosed with
HP in 2004. The treated incidence was 7.2 per 10,000
beneficiaries. These included 7,603 males, with an in-
cidence of 6.9 per 10,000 male beneficiaries, and 8,236
females, with an incidence of 7.4 per 10,000 female
beneficiaries. The incidence was significantly higher
in females than in males for all age groups, except
those aged < 20 years old. The incidence was highest
in those aged 20–29 years old. The incidence of HP
decreased with increasing age (p < 0.001) within the
total population, and among males and females
(Table 1).
Of the diagnosed patients, 3,755 (23.7%) under-
went surgery in 2004 (Table 2), including 1,733 males
(22.8% of all male patients) and 2,022 females (24.6%
of all female patients); thus, females had a significant
higher rate of undergoing surgery than males (p =
0.009). Overall, 3,728 cases (99.3%) underwent TES
and 27 cases (0.7%) underwent DS; there was no sig-
nificant sex difference between the methods used for
the operation. Most of the patients (94.7%) underwent
surgery within 1 month of the initial diagnosis; how-
ever, more males underwent surgery within 1 month
of the initial diagnosis than females (p = 0.004).
Treated incidence of hyperhidrosis
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Table 1. Age and sex-specific incidence of hyperhidrosis palmaris in Taiwan in 2004
Age (yr)
Male
Incidence*
Female
Incidence*
Total
Incidence*
cases cases cases
< 20 2,779 9.23 2,455 8.85 5,234 9.05
20–29 1,976 11.42 2,233 11.18 4,209 11.29
30–39 1,093 5.99 1,259 6.74 2,352 6.37
40–49 787 4.37 949 5.24 1,736 4.80
50–59 429 3.60 668 5.50 1,097 4.56
60–69 237 3.34 377 4.91 614 4.16
≥ 70 302 4.08 295 4.26 597 4.17
p† (M-H < 0.001 < 0.001 < 0.001
χ2 test trend)
Total 7,603 6.91 8,236 7.4 15,839 7.16
*Incidence was expressed as the identified cases per 10,000 beneficiaries; †Mantel-Haenszel χ2 test for trend according to age.
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Univariate logistic regression analysis (Table 3)
showed that females were more likely to undergo sur-
gery than males [odds ratio (OR): 1.10; 95% confidence
interval (CI): 1.02–1.19]; however, after adjustment for
other factors, this association was lost. Patients aged
20–29 years were most likely to undergo surgery
compared with the other age groups (OR: 2.87; 95%
CI: 2.62–3.15). The surgery was more commonly per-
formed at regional hospitals than at local community
hospitals or academic medical centers (OR: 6.31; 95%
CI: 5.76–6.91).
DISCUSSION
To date, no population-based studies have reported
the incidence of treatment for hyperhidrosis. A study
of a young Israeli population reported a rate of
0.6–1.0% for hyperhidrosis of all severities and loca-
tions and it was estimated that 25.0% of these indi-
viduals had severe hyperhidrosis [12]. However, this
was a pilot study and the methodology was not fully
described. Two recent studies have reported the preva-
lence of hyperhidrosis to be 2.8% within the general
population of the United States, with an average age
of 40 years [10], and 4.59% in Chinese adolescents
aged 15–22 years [9]. However, not all patients who
suffer from hyperhidrosis are willing to visit a doctor
or undergo surgery. It has been described that only
38% of subjects with reported hyperhidrosis have
discussed their sweating with a health care professional
[10], and only 0.27% of patients resort to treatment at
a clinic [9]. Here, we report incidence of treatment for
HP of only 0.072% in 2004 (7.2 patients per 10,000
Table 2. Distribution of patients with hyperhidrosis palmaris receiving surgical intervention in Taiwan in 2004*
Parameter Male Female Total p†
Total diagnosed 7,603 (100) 8,236 (100) 15,839 (100)
Received surgery 1,733 (22.8) 2,022 (24.6) 3,755 (23.7) 0.009
Surgical methods
DS 10 (0.6) 17 (0.8) 27 (0.7)
TES 1,723 (99.4) 2,005 (99.2) 3,728 (99.3) 0.340
Interval between first medical visit and operation (mo)
≤ 1 1,661 (95.8) 1,895 (93.7) 3,556 (94.7)
> 1 72 (4.2) 127 (6.3) 199 (5.3) 0.004
*Data presented as n (%); †χ2 test. DS = dorsal sympathectomy; TES = thoracic endoscopic sympathectomy.
Table 3. Factors associated with surgery for hyperhidrosis palmaris in Taiwan in 2004*
Parameter
Unadjusted
Male Female Total
Adjusted
Gender
Male 1.00 1.00
Female 1.10 (1.02–1.19) 1.06 (0.98–1.15)
Age group (yr)
< 20 1.00 1.00 1.00 1.00
20–29 3.46 (3.04–3.95) 2.38 (2.10–2.70) 2.87 (2.62–3.15) 2.28 (2.07–2.52)
30–39 1.26 (1.06–1.50) 1.30 (1.11–1.51) 1.30 (1.16–1.46) 1.17 (1.04–1.31)
40–49 0.52 (0.40–0.66) 0.56 (0.46–0.68) 0.55 (0.47–0.65) 0.61 (0.52–0.71)
50–59 0.25 (0.16–0.39) 0.18 (0.16–0.26) 0.21 (0.16–0.28) 0.27 (0.21–0.36)
60–69 0.16 (0.08–0.32) 0.04 (0.01–0.10) 0.08 (0.04–0.14) 0.10 (0.06–0.19)
≥ 70 0.01 (0.00–0.11) 0.00 0.01 (0.00–0.05) 0.01 (0.00–0.06)
Hospital classification
Locl community hospital 1.00 1.00 1.00 1.00
Regional hospital 8.85 (7.72–10.14) 4.76 (4.21–5.37) 6.31 (5.76–6.91) 4.87 (4.41–5.37)
Academic medical center 7.91 (6.79–9.21) 4.92 (4.28–5.66) 6.13 (5.53–6.79) 4.65 (4.21–5.12)
*Data presented as odd ratio (95% confidence interval).
beneficiaries). Our data include patients presenting
for treatment and those who actually need medical
services. The need for treatment is a result of the
interaction between the severity of the hyperhidrosis
and the tolerance of the patient to hyperhidrosis.
Compared with subjects with hyperhidrosis iden-
tified by a general survey, patients who received treat-
ment had more severe hyperhidrosis. In a general
survey, 93.87% of subjects were found to have low-
grade severity and only 6.12% of subjects had high-
grade severity [9]. Conversely, in a study of 508 patients
who were referred for botulinum toxin therapy, 90.2%
of the patients had a higher grade of severity [8].
The age of onset of primary hyperhidrosis was
found to be 73% during childhood, 22% during ado-
lescence and 5% during adulthood [1,6]. However,
people may not seek medical help until early adult-
hood [7]. The mean age of onset (14.05 years old) 
and the mean age at consultation (28.11 years old) [8]
differ by about 14 years. The severity and frequency
of sweating seems to decrease in older patients, such
as those older than 50 years of age [7,9]. Therefore,
the reported prevalence among adolescents (4.59%)
[9] may be higher than that of adults (2.8%) [10]. The
delay in seeking medical service and the decreasing
severity with aging explain the peak in incidence of
treated HP at 20–29 years old in our series.
Previous studies have suggested that both sexes
are affected equally [9,10,13] and there is currently 
no evidence of sex-linked genetic transmission [2].
However, females are more likely than males to dis-
cuss sweating with a health care professional [8,10].
The higher incidence of treated HP among females 
in our series indicates greater willingness of females 
to attend a physician. Although the univariate analysis
revealed females were more likely to undergo surgery
than males, this association was lost after adjusting
for age. Interestingly, not withstanding this signifi-
cant sex difference, males underwent surgery sooner
after attending the outpatient clinic than females did.
In this study, 23.7% of patients underwent surgery
and 99.3% of these underwent TES. About 94.7% pa-
tients underwent surgery within 1 month after they
first attended a clinic. TES has been used for cases 
of HP since around 1989 in Taiwan [1,6,19–21] and
has become the standard procedure and treatment 
of choice for hyperhidrosis by neurosurgeons and
thoracic surgeons worldwide [12,17,18,24–26]. The
quality of life of the patient is generally improved
after surgery and the overall patient satisfaction rate
was reported to be 78–86% [1,6,19,20]. The long-term
outcomes of TES still need to be fully evaluated. In
this context, regional hospitals showed the highest
utilization of this procedure, which may be due to
better accessibility of the regional hospitals.
The most important and interesting epidemiological
finding for HP is the proportion of patients who seek
medical care and, of these, the number that receive an
operation; this information is much more useful than
the prevalence of the disease in the general popula-
tion. Thus, we have reported important information
on the incidence of treatment for HP. We conclude
that the incidence of HP is highest in females and the
peak incidence of treated HP is at 20–29 years old.
About one-quarter of patients undergo surgery to
treat this disease. In Taiwan, surgery was mostly per-
formed within 1 month of the patient first attending
an outpatient clinic and almost all cases were treated
using TES.
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台灣在手多汗症手術之治療居於世界領先的地位，但全世界均無手多汗症發生率之報
告，亦無其接受手術治療狀況之分析。以台灣 2002 年至 2006 年之健保資料庫，排
除前兩年曾因手多汗症主診斷就醫者後，分析在 2004 年因手多汗症主診斷者 (ICD-9 
碼 780.8) 就醫之病例及發生率、接受交感神經切除術 (83026C 胸交感神經切除術，
83085B 經胸內視鏡交感神經切除術 ) 之人數、時間、性別及年齡。有 15,839 手多汗
症新就診例，發生率為每萬人 7.2 例，男性發生率每萬人 6.9 人，女性為每萬人 7.4 
人。以 20–29 歲之病患為最多，並依年齡遞增而遞減 （M-H 卡方趨勢測驗，p < 
0.001）。有 3,755 例接受手術 （23.7%），99.3% 為經胸內視鏡交感神經切除術， 
94.7% 在就診後一個月內手術。男女接受手術之機會無顯著差異； 20–29 歲之族群相
較於其他族群有較高之手術機會 （OR = 2.28，95%CI = 2.07–2.52），並隨年齡遞
減；在區域醫院接受手術之機會為最高（OR = 4.87，95%CI = 4.41–5.37）。我們
分析手多汗症之性別年齡別發生率，及影響手術治療之因素。經胸內視鏡手術顯然在
台灣極為普及，在可近性高之區域醫院執行最多。本篇報告補充了手汗症在流行病學
研究之缺口，可供臨床醫師及醫療行政決策使用。
關鍵詞：內視鏡、手多汗症、發生率、交感神經切除術
（高雄醫誌 2010;26:123–9）
